PT-141 Dosage: How Bremelanotide Is Dosed Under Medical Supervision

Under medical supervision, PT-141 dosage is anchored to the only FDA-approved reference point for bremelanotide: Vyleesi, dosed at 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than 8 doses per month. Any off-label or compounded PT-141 dosing is determined individually by a licensed provider and is not standardized by the FDA. This is educational information, not medical advice; PT-141 is prescription-only, so talk to a licensed provider.

What PT-141 is and how it works

PT-141 is bremelanotide, a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. It activates melanocortin receptors in the central nervous system (primarily MC4R, and also MC3R) within the hypothalamus, influencing dopamine and oxytocin signaling involved in sexual desire and arousal. In other words, it works centrally, in the brain. That mechanism is different from PDE5 inhibitors such as sildenafil (Viagra) and tadalafil (Cialis), which act peripherally on genital blood flow. Because bremelanotide targets desire pathways rather than vascular flow, clinicians think about its dosing and timing differently than they would a PDE5 inhibitor.

The approved dosing reference (Vyleesi)

When clinicians talk about how bremelanotide is dosed, the anchor is the FDA-approved product, Vyleesi. Vyleesi was approved on June 21, 2019, for premenopausal women with acquired, generalized HSDD. It is supplied as 1.75 mg in 0.3 mL and is self-administered subcutaneously using a prefilled autoinjector into the abdomen or the thigh. The label directs use at least 45 minutes before anticipated sexual activity, with a ceiling of one dose in any 24-hour period and no more than 8 doses per month. Those numbers are the reference framework a provider starts from, even when the clinical situation falls outside the approved population.

It is important to be precise here: Vyleesi is FDA-approved only for premenopausal women with HSDD. It is not FDA-approved for men or for erectile dysfunction. Any use outside that indication, and any compounded version of PT-141, is off-label and not FDA-approved.

Timing

The approved reference calls for administration at least 45 minutes ahead of anticipated activity, reflecting how long the medication takes to reach an effect. Timing is a dosing decision, not an afterthought, and a provider will discuss how it fits an individual situation.

Titration and starting low

Because tolerability (especially nausea) is the most common reason people struggle with bremelanotide, clinicians generally favor caution and individualization rather than escalation. For off-label or compounded preparations there is no FDA-standardized strength or titration schedule, so a licensed provider decides what, if anything, is appropriate and how to adjust based on your response and side effects.

Maximum frequency

The approved reference caps dosing at one dose per 24 hours and 8 doses per month. These frequency limits exist for safety reasons, including cardiovascular effects and the risk of skin darkening with repeated or frequent use, discussed below.

Наблюдение

Bremelanotide is prescription-only precisely because it requires screening and follow-up. A provider reviews blood pressure, cardiovascular history, current medications, and your response over time. Monitoring is part of dosing, not separate from it.

Approved reference vs off-label compounded dosing

The table below contrasts the FDA-approved Vyleesi parameters with off-label compounded PT-141, where dosing is provider-determined rather than FDA-standardized. It is a comparison of frameworks, not a protocol to follow on your own.

Параметр	Vyleesi (FDA-approved reference)	Off-label / compounded PT-141
Нормативно-правовой статус	FDA-approved for premenopausal women with acquired, generalized HSDD	Off-label; not FDA-approved; prepared by a licensed compounding pharmacy and not FDA-reviewed for safety, effectiveness, or quality
Reference dose	1.75 mg in 0.3 mL	Not FDA-standardized; provider-determined
Способ применения	Subcutaneous autoinjector (abdomen or thigh)	Subcutaneous injection or, off-label, nasal spray (nasal forms not FDA-approved, less rigorous evidence)
Timing reference	At least 45 minutes before anticipated activity	Определяется лечащим врачом
Max per 24 hours	1 dose	Определяется лечащим врачом
Max per month	8 doses	Определяется лечащим врачом
Who sets the dose	инструкции, одобренной FDA	Individual licensed provider

Что показывают данные

In the women’s HSDD program (the phase 3 RECONNECT trials), Vyleesi improved sexual desire and reduced associated distress compared with placebo. Those are the findings that supported approval in premenopausal women. In men, earlier bremelanotide studies, including a subset of men who had not responded to sildenafil, reported improvements in erectile response. However, bremelanotide is not FDA-approved for men, and those earlier findings do not establish approved efficacy. Male and erectile-dysfunction use should be understood as investigational and off-label. Trial figures describe what was observed in studies; they are not promises of a result for any individual.

FDA and 503A regulatory status

Being precise about status matters for a medication like this. Bremelanotide is FDA-approved only as Vyleesi, and only for premenopausal women with acquired, generalized HSDD. Any use in men, any use for erectile dysfunction, and any compounded PT-141 (including nasal-spray formulations) is off-label and not FDA-approved.

Compounded PT-141 is prepared by licensed pharmacies, is prescription-only, and is not reviewed by the FDA for safety, effectiveness, or quality the way an approved product is. Compounding under section 503A allows a licensed pharmacy to prepare a medication for an individual patient pursuant to a valid prescription, but that is not the same as FDA approval of the finished product. This is why responsible use is always provider-led: a clinician determines whether any form or dose is appropriate for you.

Safety and side effects

The most common adverse effects reported with bremelanotide are nausea (about 40% in trials), flushing (about 20%), headache (about 11%), and injection-site reactions. Bremelanotide also causes transient increases in blood pressure (roughly 6 mmHg systolic and 3 mmHg diastolic) and decreases in heart rate for several hours after a dose. For that reason it is not recommended for people with uncontrolled hypertension or known cardiovascular disease. With repeated use, focal hyperpigmentation (darkening of the skin, face, or gums) can occur, and it is more likely with daily dosing, which is one reason frequency limits exist. Because these effects need screening and follow-up, bremelanotide is prescription-only and a licensed provider checks for contraindications and monitors over time.

Who is a candidate

Candidacy is a clinical decision, not a self-assessment. A provider considers your reason for seeking treatment, your cardiovascular and blood-pressure history, your current medications, prior response to other therapies, and your goals. People with uncontrolled hypertension or known cardiovascular disease are generally not appropriate candidates. Because Vyleesi is approved only for premenopausal women with HSDD, any other use is off-label and requires a provider to weigh potential benefits against risks for your specific situation.

Как к этому подходит Revive

Revive Longevity is prescription-only and provider-led. Where Revive dispenses PT-141, it is a compounded preparation from a licensed pharmacy (not the branded Vyleesi), used off-label, and only where a licensed provider determines it is appropriate. It is not FDA-approved, and a provider determines eligibility, the form, and any dosing after reviewing your history and screening for contraindications. If you are curious whether this fits your situation, you can learn more on the PT-141 page and see the provider-led process on how Revive works. We do not provide self-dosing instructions; the point of a supervised model is that a clinician, not a web page, makes those decisions with you.

Часто задаваемые вопросы

What is the standard PT-141 dosage?

There is no FDA-standardized dose for off-label or compounded PT-141. The only FDA-approved dosing reference for bremelanotide is Vyleesi: 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than 8 doses per month. Any off-label or compounded dosing is determined individually by a licensed provider.

How long before activity is bremelanotide taken?

The approved Vyleesi reference directs administration at least 45 minutes before anticipated sexual activity. Timing for any off-label or compounded use is provider-determined. This is a reference framework, not a self-dosing instruction.

How often can it be dosed?

The approved reference caps use at one dose in any 24-hour period and no more than 8 doses per month. These limits exist for safety, including transient cardiovascular effects and the risk of skin darkening with frequent or daily use. A provider sets frequency for any off-label use.

Is compounded PT-141 FDA-approved?

No. Bremelanotide is FDA-approved only as Vyleesi for premenopausal women with acquired, generalized HSDD. Compounded PT-141, including nasal sprays, is off-label and not FDA-approved. It is prepared by licensed pharmacies, is prescription-only, and is not reviewed by the FDA for safety, effectiveness, or quality.

Is PT-141 dosing different for men?

Bremelanotide is not FDA-approved for men or for erectile dysfunction, so there is no FDA-approved dosing for men. Earlier studies in men reported improvements in erectile response, but those findings are investigational and do not establish approved efficacy. Any use in men is off-label and provider-determined.

Do I need a prescription and monitoring?

Yes. PT-141 is prescription-only. A licensed provider screens for contraindications (such as uncontrolled hypertension or known cardiovascular disease), determines whether treatment is appropriate, and monitors your response. This page is educational and is not a substitute for that evaluation.